In a meta-analysis of 150 cases to compare gene mutational profiles across MDS, MDS/MPN, and MPN, the results confirmed the low frequency of JAK2 mutations in MDS and its more frequent occurrence among myeloproliferative neoplasms and cases with overlap features, particularly MDS/MPN-RS-T [19]. This evidence concerns the gene JAK2 and myeloproliferative disorder.